Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709683 | 0.85 | TSHR (0.62) | GAAKDM4EHTTTSHRALDH1A1 | |
| SCHEMBL11131291 | 0.84 | GAA (0.50) | CYP2C9CYP2C19GAAKDM4EHTT | |
| SCHEMBL11853033 | 0.82 | GAA (0.68) | GAAKDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31000980 | 0.82 | GAA (0.68) | GAAKDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1468205 | 0.82 | CYP2D6 (0.50) | HTTTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2269853 | 0.82 | ALDH1A1 (0.52) | KDM4EHTTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3166437 | 0.82 | HTT (0.47) | CYP2C9CYP2C19HTTTSHRALDH1A1 | |
| SCHEMBL16494957 | 0.81 | PKM (0.56) | CYP2C9CYP2C19GAAHTTALDH1A1 | |
| SCHEMBL28016378 | 0.80 | PPARG (0.48) | GAAKDM4EHTTTSHRSMN1; SMN2 | |
| SCHEMBL16220186 | 0.78 | KMT2A (0.50) | GAAHTTTSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352921-A1 | ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS | CALYGENE BIOTECHNOLGY INC (US) | 2020-11-12 | — | — | US | disclosed |
| CN-110117264-A | Phenyl sulfone derivative and its application on drug | 广东东阳光药业有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-101309910-A | Process for obtaining valine derivatives for obtaining pharmaceutically active compounds | INKE SA (ES) | 2008-11-19 | — | — | CN | disclosed |
| US-7026339-B2 | Inhibitors of HCV NS5B polymerase | PFIZER INC. | 2006-04-11 | — | — | US | disclosed |
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | PHARMACIA & UPJOHN COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352921-A1 | ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS | TRPM6, TRPM2, TRPM5 | CYP2C9 3543/4885CYP2C19 2613/4885GAA 42/4885 |
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | ACACB, HCCS, HAVCR2 | CYP2C9 224/4885CYP2C19 661/4885GAA 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.